Paratek Pharmaceuticals, Inc. (PRTK)

NASDAQ: PRTK · IEX Real-Time Price · USD
2.09
-0.02 (-0.95%)
Jan 27, 2023, 4:30 PM EST - Market closed
-0.95%
Market Cap 116.10M
Revenue (ttm) 116.51M
Net Income (ttm) -88.66M
Shares Out 55.55M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE 1.72
Dividend n/a
Ex-Dividend Date n/a
Volume 205,393
Open 2.10
Previous Close 2.11
Day's Range 2.07 - 2.14
52-Week Range 1.60 - 4.37
Beta 1.48
Analysts Buy
Price Target 18.36 (+778.47%)
Earnings Date Mar 13, 2023

About PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Evan Loh
Employees 207
Stock Exchange NASDAQ
Ticker Symbol PRTK
Full Company Profile

Financial Performance

In 2021, PRTK's revenue was $130.16 million, an increase of 177.39% compared to the previous year's $46.92 million. Losses were -$59.08 million, -38.80% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PRTK stock is "Buy." The 12-month stock price forecast is $18.36, which is an increase of 778.47% from the latest price.

Price Target
$18.36
(778.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections National Healthcare Secur...

1 week ago - GlobeNewsWire

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its fir...

1 month ago - GlobeNewsWire

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA's effectiveness in th...

1 month ago - GlobeNewsWire

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

2 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

2 months ago - GlobeNewsWire

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021

3 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

3 months ago - GlobeNewsWire

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follo...

3 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p...

3 months ago - GlobeNewsWire

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

Highlights include data from non-clinical and microbiology programs and real-world patient use

3 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek's Management Team Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek's Management Team

4 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...

5 months ago - GlobeNewsWire

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021

6 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 ...

6 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

8 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...

9 months ago - GlobeNewsWire

Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021

9 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 ...

9 months ago - GlobeNewsWire

Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Pr...

11 months ago - GlobeNewsWire

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 ...

11 months ago - GlobeNewsWire

China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections

Paratek earns $6 million milestone payment from Zai Lab Paratek earns $6 million milestone payment from Zai Lab

1 year ago - GlobeNewsWire

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research